Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma

British Journal of Cancer

Volumn 107, Issue 1, 2012, Pages 116-122

  Dyrskjot L ^a   Zieger, K ^a   Kissow Lildal, T ^a   Reinert, T ^a   Gruselle, O ^b   Coche, T ^b   Borre, M ^a   Orntoft T F ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Bladder cancer; CT genes; immunotherapy; PCR; prognosis

Indexed keywords

CANCER TESTIS ANTIGEN; LAGE 1 PROTEIN; MELANOMA ANTIGEN 3; NY ESO 1 ANTIGEN; PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLADDER CANCER; CANCER INVASION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; GENE EXPRESSION; HUMANS; MALE; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 84863001652     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.215     Document Type: Article

References (29)

1. Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, Elting LS (2006) Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68(3): 549-553 (Pubitemid 44436509)
2. Bergeron A, Picard V, LaRue H, Harel F, Hovington H, Lacombe L, Fradet Y (2009) High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer 125(6): 1365-1371
3. Caballero OL, Chen YT (2009) Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100(11): 2014-2021
4. De Carvalho DD, Binato R, Pereira WO, Leroy JM, Colassanti MD, Proto-Siqueira R, Bueno-Da-Silva AE, Zago MA, Zanichelli MA, Abdelhay E, Castro FA, Jacysyn JF, Amarante-Mendes GP (2011) BCRABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. Oncogene 30(2): 223-233
5. Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R (2008) PRAME expression and clinical outcome of breast cancer. Br J Cancer 99(3): 398-403
6. Francois V, Ottaviani S, Renkvist N, Stockis J, Schuler G, Thielemans K Colau D, Marchand M, Boon T, Lucas S, van der Bruggen P (2009) The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res 69(10): 4335-4345
7. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ, Altorki NK (2005) Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 11(22): 8055-8062 (Pubitemid 41698748)
8. Hermann GG, Horn T, Steven K (1998) The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol 159(1): 91-94 (Pubitemid 27525578)
9. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics (2010) CA Cancer J Clin 60(5): 277-300
10. Knuth A, Wolfel T, Klehmann E, Boon T, Meyer zum Buschenfelde KH (1989) Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci USA 86(8): 2804-2808 (Pubitemid 19112628)
11. Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, Jungbluth A, Ritter G, Chen YT, Stockert E, Tsushima T, Kumon H, Old LJ, Nakayama E (2001) Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res 61(12): 4671-4674 (Pubitemid 32691873)
12. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J (2000) Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 164(3 Pt 1): 680-684 (Pubitemid 30637601)
13. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M, Schneider C (2006) MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 103(30): 11160-11165 (Pubitemid 44156489)
14. Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K, Murai M (2001) Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res 7(1): 23-31 (Pubitemid 32110201)
15. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S (2007) Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA 104(31): 12837-12842 (Pubitemid 47255241)
16. Old LJ (2008) Cancer vaccines: an overview. Cancer Immun 8(Suppl 1): 1
17. Patard JJ, Brasseur F, Gil-Diez S, Radvanyi F, Marchand M, Francois P, Abi-Aad A, Van Cangh P, Abbou CC, Chopin D, Boon T (1995) Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer 64(1): 60-64
18. Perez D, Hauswirth F, Jager D, Metzger U, Samartzis EP, Went P, Jungbluth A (2011) Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors. Int J Cancer 128(12): 2947-2952
19. Picard V, Bergeron A, Larue H, Fradet Y (2007) MAGE-A9 mRNA and protein expression in bladder cancer. Int J Cancer 120(10): 2170-2177 (Pubitemid 46555854)
20. Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL, Wiuf C, Borre M, Dyrskjot L, Orntoft TF (2011) Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res 17(17): 5582-5592
21. Santamaria C, Chillon MC, Garcia-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Ramos F, Bernal T, Queizan JA, Penarrubia MJ, Giraldo P, San Miguel JF, Gonzalez M (2008) The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. Haematologica 93(12): 1797-1805
22. Sharma P, Gnjatic S, Jungbluth AA, Williamson B, Herr H, Stockert E, Dalbagni G, Donat SM, Reuter VE, Santiago D, Chen YT, Bajorin DF, Old LJ (2003) Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun 3: 19
23. Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA (2006) Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 12(18): 5442-5447 (Pubitemid 44497259)
24. Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M, Maio M (2004) Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res 64(24): 9167-9171 (Pubitemid 39665532)
25. Simons MP, O'Donnell MA, Griffith TS (2008) Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol 26(4): 341-345 (Pubitemid 351885380)
26. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5(8): 615-625 (Pubitemid 41081387)
27. Suyama T, Shiraishi T, Zeng Y, Yu W, Parekh N, Vessella RL, Luo J, Getzenberg RH, Kulkarni P (2010) Expression of cancer/testis antigens in prostate cancer is associated with disease progression. Prostate 70(16): 1778-1787
28. Uenaka A, Wada H, Isobe M, Saika T, Tsuji K, Sato E, Sato S, Noguchi Y, Kawabata R, Yasuda T, Doki Y, Kumon H, Iwatsuki K, Shiku H, Monden M, Jungbluth AA, Ritter G, Murphy R, Hoffman E, Old LJ, Nakayama E (2007) T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun 7: 9
29. Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC, Resnick MB (2003) Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res 9(17): 6453-6460 (Pubitemid 38031833)